Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003-2004)

International Journal of Antimicrobial Agents
David J FarrellWaleria Hryniewicz

Abstract

The distribution and antibacterial susceptibility of macrolide resistance genotypes among 7083 Streptococcus pneumoniae isolates collected worldwide during 2003-2004 from patients with community-acquired respiratory tract infections, including patients within 48h of admission to hospital, were analysed. The overall rate of erythromycin resistance was 37.2% (intercountry range <10% to >50%). The most common resistance mechanism globally was erm(B) (55.0% of erythromycin-resistant S. pneumoniae (ERSP)), followed by mef(A) (30.6%) and erm(B)+mef(A) (12.0%). Genotype distribution varied by age group (P<0.0001); erm(B)+mef(A) was more prevalent (21.8% of isolates) among patients 0-2 years of age than among other age groups (P<0.001). The prevalence of tetracycline resistance among mef(A) isolates varied between different countries. Of the erm(B)+mef(A) strains, 43.5% were resistant to amoxicillin/clavulanic acid. Most ERSP isolates were susceptible to levofloxacin (98.3%) and telithromycin (99.4%).

References

Sep 20, 2002·The Journal of Antimicrobial Chemotherapy·David Felmingham
Jan 9, 2004·Expert Review of Vaccines·Katherine K Hsu, Stephen I Pelton
May 6, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paul H Edelstein
Mar 18, 2005·The Journal of Antimicrobial Chemotherapy·Michael T HalpernLionel A Mandell
Jun 21, 2005·Emerging Infectious Diseases·Keith P Klugman, John R Lonks
Jun 21, 2005·Emerging Infectious Diseases·David J FarrellKeith P Klugman
Mar 7, 2006·Journal of Clinical Microbiology·Bernard BeallUNKNOWN Active Bacterial Core Surveillance Team
Jul 14, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·N DanemanUNKNOWN Toronto Invasive Bacterial Diseases Network

❮ Previous
Next ❯

Citations

Apr 6, 2012·Current Infectious Disease Reports·Sadao Jinno, Michael R Jacobs
Apr 23, 2011·The Journal of Antimicrobial Chemotherapy·Takafumi SatoNaomasa Gotoh
Jul 9, 2010·Clinical Microbiology Reviews·Soichiro Kanoh, Bruce K Rubin
Oct 13, 2012·BMC Infectious Diseases·Ioanna N GriveaGeorge A Syrogiannopoulos
Jun 8, 2012·International Journal of General Medicine·José BarberánMaría-José Giménez
Jul 5, 2011·Drugs & Aging·Ulrich ThiemLudger Pientka
Aug 3, 2010·Infectious Disease Clinics of North America·Jae-Hoon Song, Doo Ryeon Chung
Jun 19, 2010·International Journal of Antimicrobial Agents·Ronald N JonesHelio S Sader
Apr 5, 2011·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Murat TelliNeriman Aydın
Aug 15, 2014·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Paulina A HawkinsLesley McGee
Apr 25, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·R R Reinert
Oct 7, 2016·Frontiers in Cellular and Infection Microbiology·Max R Schroeder, David S Stephens
Jun 9, 2018·Expert Review of Respiratory Medicine·Nicola Principi, Susanna Esposito
Jun 30, 2016·Antimicrobial Agents and Chemotherapy·Hana Čipčić PaljetakVesna Eraković Haber
Oct 22, 2013·Expert Review of Respiratory Medicine·Jae-Hoon Song
Aug 17, 2016·Cold Spring Harbor Perspectives in Medicine·Corey FyfeJoyce Sutcliffe
Dec 3, 2016·The Journal of Antibiotics·Prabhavathi FernandesDavid Pereira
Sep 21, 2017·Emerging Infectious Diseases·Takaaki TanakaKazunobu Ouchi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.